Renan Ribeiro e Ribeiro

Renan Ribeiro e Ribeiro

Auto-generated profile, based on publicly available information

Renan Ribeiro e Ribeiro

CICAP-Hospital Alemão Oswaldo Cruz , São Paulo , Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
ADAndre Roncon Dias
Andre Roncon Dias
LCLeonardo Cardili
Leonardo Cardili
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
EMEvandro Sobroza de Mello
Evandro Sobroza de Mello

24 October 2020 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
ADAndré Roncon Dias
André Roncon Dias
RRRenan Ribeiro
Renan Ribeiro
LCLeonardo Cardili
Leonardo Cardili
Tiago Biachi de CastriaTiago Biachi de Castria
Tiago Biachi de Castria

15 July 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
Tiago Biachi de CastriaTiago Biachi de Castria
Tiago Biachi de Castria
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
LCLeonardo Cardili
Leonardo Cardili
ICIvan Cecconello
Ivan Cecconello

5 January 2024 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
CSC. James Sung
C. James Sung
MQMd M. Ruhul Quddus
Md M. Ruhul Quddus
Context.—: There have been exceedingly few reports of epidermodysplasia verruciformis (EV) or EV-like lesions in the vulva. We describe the first observation of vulvar lesions displaying synchronous EV-like histology and conventional high-grade squamous intraepithelial lesion (HSIL), a finding hitherto unreported in medical literature. Objectives.—: To describe this novel vulvar lesion with hybrid features of HSIL and EV, attempt to confirm the hypothesis of coinfection with α and β human papillomavirus (α-HPV and β-HPV) genotypes, and describe relevant underlying genetic mutations. Design.—: Cases were retrospectively selected from our institutional archive. Detailed review of clinical information, histologic examination, and whole genome sequencing (WGS) were performed. Results.—: Five samples from 4 different patients were included. Three of 4 patients had a history of either iatrogenic immune suppression or prior immune deficiency, and all 3 featured classic HSIL and EV changes within the same lesion. One patient had no history of immune disorders, presented with EV-like changes and multinucleated atypia of the vulva, and was the sole patient without conventional HSIL. By WGS, several uniquely mappable reads pointed toward infection with multiple HPV genotypes, including both α-HPVs and β-HPVs. Mutations in genes implicated in cell-mediated immunity, such as DOCK8, CARMIL2, MST1, and others, were also found. Conclusions.—: We provide the first description of vulvar lesions harboring simultaneous HSIL and EV features in the English-language literature, a phenomenon explained by coinfection with α-HPV and β-HPV genotypes. The finding of EV-like changes in a vulvar specimen should prompt assessment of the patient’s immune status.

1 May 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
AVAshley Valenzuela
Ashley Valenzuela
LBLindsey Beffa
Lindsey Beffa
CSC. James Sung
C. James Sung
MQM. Ruhul Quddus
M. Ruhul Quddus
• Bilateral ovarian low-grade serous carcinoma presenting with extensive osseous metaplasia. • Both lesions arising directly from ovarian cystadenofibromas, skipping the “borderline phase”. • No micropapillary serous borderline component was identified. • This case may represent a “skipped step” in low-grade serous carcinogenesis.

1 January 2026 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
LOLuiz Felipe Lessa Ortiz
Luiz Felipe Lessa Ortiz
RMRafael Dyer Rodrigues de Moraes
Rafael Dyer Rodrigues de Moraes
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
CRCaio Bosquê Hidalgo Ribeiro
Caio Bosquê Hidalgo Ribeiro
ALAmanda Lino De Faria Lessa
Amanda Lino De Faria Lessa
GBGiorgio Bogani
Giorgio Bogani
Managing G2 endometrioid endometrial adenocarcinoma without progesterone receptor (PR) expression presents significant challenges, particularly when considering fertility preservation. Grade 2 tumors fall into an area of uncertainty within fertility‐sparing strategies, making treatment decisions complex and requiring careful individualization. This case report describes a 41‐year‐old patient who, despite PR and PE negativity, responded to conservative management with hysteroscopic resection, a levonorgestrel‐releasing intrauterine device, metformin, and later megestrol, achieving complete histological remission in 15 months. The difficulty in managing G2 tumors lies in their variable behavior, necessitating a multidisciplinary approach, strict monitoring, and adaptability based on treatment response. This case underscores that, although fertility preservation in PR‐negative G2 tumors remains challenging, it is feasible in highly selected cases. The evolving literature suggests that alternative strategies, such as immune modulation and aromatase inhibitors, may further expand options. Individualized management remains crucial, balancing oncological safety with reproductive goals through continuous reassessment and engagement with emerging therapeutic evidence.